Abuse of Recombinant Human Growth Hormone: Studies in Two Different Dog Models

  title={Abuse of Recombinant Human Growth Hormone: Studies in Two Different Dog Models},
  author={Antonello Emilio Rigamonti and Diego Scanniffio and Sara M Bonomo and Silvano G. Cella and Alessandro Sartorio and Eugenio E. M{\"u}ller},
  pages={237 - 246}
The search for inappropriately high growth hormone (GH) titers in plasma has been widely used to detect GH abuse, despite many shortcomings especially related to the pulsatile nature of GH secretion. Hence, the need for new anti-doping strategies. In the present study dogs were used to evaluate the ability of recombinant human GH (rhGH) to affect canine GH (cGH) release ensuing after somatostatin (SS) infusion withdrawal (SSIW) – a purported stimulus for the release of endogenous GH-releasing… 

Figures and Tables from this paper

Testosterone Inhibition of Growth Hormone Release Stimulated by a Growth Hormone Secretagogue
These studies show that a single administration of testosterone can abrogate the cGH response ensuing acute stimulation by a GHS; the inhibitory effect of testosterone on the c GH response to GHS is present during and even 8 days after termination of a short-lived treatment with testosterone; these events occur via a downregulation of hypothalamic GHS-R.
Insulin-like growth factor I concentration in dogs with inflammatory and neoplastic liver diseases.
Investigation in dogs with primary liver diseases showed that dogs with liver diseases had significantly lower IGF-I serum concentrations than clinical healthy dogs or dogs with non-hepatic diseases, but the results indicate that the aetiology of liver disease has no influence on IGF- I serum concentration.
Small-intestinal myoelectric activity in sheep: rebound excitation versus phase-3-like activity revealed by hexamethonium and atropine administration
It is concluded that Hx and At inhibit small-intestinal motility and evoke RE and phase-3-like activity as a secondary stimulatory response in conscious sheep.
Osteopenia in pediatric patients : when and and how to intervene ?
  • Medicine
  • 2005
This bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press.


Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
The uniformity of the GH rebound responses to multiple cycles of SSIW may indicate that the latter activate a physiological mechanism which mimics that normally controlling GH pulse generation.
Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.
Findings are compatible with the view that an age-related decrease in endogenous GHRH function may contribute to the defective GH secretion of the elderly.
Pharmacological and Toxicological Effects of Chronic Porcine Growth Hormone Administration in Dogs
The dog is a good model in which to evaluate the safety of GH secretagogues as well as compounds with GH-like activity, and there was no chronic hyperglycemia based on glycosylated hemoglobin levels.
Somatostatin infusion withdrawal: studies in normal children and in children with growth hormone deficiency.
It is demonstrated that SSIW elicits a significant GH rise in NC children, but not in GH-deficient children, regardless of the underlying etiology, and holds promise of being a useful diagnostic tool for GH-dependent growth disorders.
GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
GH-releasing peptides (GHRPs), a class of small synthetic peptide and non-peptide compounds, act on specific receptors at both the pituitary and the hypothalamic level to stimulate GH release in both
Somatostatin and its Physiological Significance in Regulating the Episodic Secretion of Growth Hormone in the Rat
Sex differences in GH secretion are also reflected in the expression of several GH‐dependent liver enzymes, one of which, carbonic anhydrase III, responds to manipulations of the endogenous secretory pattern by SS in both normal and dwarf rats, and appears to be sensitive to differences in basal, rather than peak, GH levels.
Withdrawal of endogenous somatostatin induces secretion of growth hormone-releasing factor in rats.
It is investigated whether acute withdrawal of SRIF can induce GRF release by the rat hypothalamus using highly specific antisera against SRIF and rat GRF and in urethane-anaesthetized rats an acute phasic GH release was caused by SRIF antiserum despite the interference of anaesthesia with spontaneous GH secretion.
Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action.
It is concluded that the hypothalamus is a major target for GHRP-6 in vivo, and it is suggested that somatostatin may block this activation via receptors known to be located on or near the GRF cells themselves.
Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects.
Owing to its tolerability and its suitability for use in the elderly, the GHRH + arginine test is the best alternative choice and is at least as sensitive as the ITT provided that appropriate cut-off limits are given.